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Natural Killer (NK) cells represent innate effector cells potentially able to play a role during the 
immune response against Multiple Myeloma (MM). 
 
To better define the distribution and the specific properties of NK cell subsets during MM disease, 
we analyzed their features in the bone marrow and peripheral blood of newly diagnosed MM 
patients. Our findings revealed that, in both compartments, NK cells were more abundant than in 




 NK cell 
subset was observed, which already appears in clinical precursor conditions leading to MM, namely 
monoclonal gammopathy of undetermined significance and smoldering MM, and eventually 





cells was in a proliferation phase. When analyzed for their killing abilities, they represented the 
main cytotoxic NK cell subset against autologous MM cells. 
 




 NK cell subset, 
thus reminiscent of that observed in MM patients. Mechanistically, this accumulation relied on cell 
to cell contacts between MM and NK cells and required both activation via DNAM-1 and 
homophilic interaction with CD56 expressed on MM cells. 
 
Considering the growing variety of combination treatments aimed at enhancing NK cell-mediated 


































Multiple Myeloma (MM) is a hematologic malignancy characterized by a monoclonal expansion of 
malignant plasma cells (PCs) within the bone marrow (BM), often accompanied by osteolytic bone 
lesions and modifications of normal immune responses.
1
 MM represents about 1% of total neoplastic 
diseases, and 13% of hematologic cancers, currently the treatments rely on autologous stem cell 
transplantation and subministration of several classes of drugs, such as alkylating agents 
(melphalan), IMiDs (thalidomide, lenalidomide) or proteasome inhibitors (bortezomib). New 
treatment protocols have improved the management of MM course, and extended patients survival, 
though this pathology is still classified as incurable. 
 
The clonal proliferation of malignant PCs in the bone marrow microenvironment is associated with 
increase in the level of monoclonal (M) protein in blood and serum. Myeloma cells are characterized 
by high rates of somatic hypermutation of immunoglobulin (Ig) genes and isotype class switching, 
but differ from healthy PCs with respect to the abundance of certain cell surface molecules, including 
CD138 and CD38. 
 
MM arises consistently from asymptomatic precursor conditions, specifically monoclonal 
gammopathy of undetermined significance (MGUS) and smoldering MM (sMM) (Figure 1), with a 
cumulative risk of overall progression of 1% and 10% per year, respectively.
2,3
 
MM evolves from these premalignant disorders via progressive molecular events that lead to altered 
plasma cell surface protein expression, such as loss or decrease of CD45 molecules, aberrant 
 
expression of neural cell adhesion molecule (NCAM-1/CD56)
4
 and abnormally enhanced 






























Figure 1. Progression of Multiple Myeloma 
 
 
Natural Killer cells 
 
 
Natural Killer (NK) cells are innate lymphocytes involved in the initiation, enhancement, and 
regulation of anti-tumor immune response and in the control of viral infection spreading. 
 
NK cells express a wide range of activating and inhibitory receptors, as well as adhesion and co-
stimulatory molecules, allowing them to recognize and kill infected or transformed cells
6,7
, whereas 
they are prevented from attacking normal tissues by the interaction between major histocompatibility 
complex (MHC) class I molecules and MHC-class I-specific inhibitory receptors. 
 
Therefore, in the absence or down-regulation of MHC class I expression, for example, on tumor cells 
or virus-infected cells, engagement of the activating receptors on NK cells by the corresponding 
ligands triggers target cell killing. 
 
NK cells represent 5-10% of circulating lymphocytes, but they are widely present in other tissue 
compartments. In particular, they are abundant in secondary lymphoid tissues (lymph node, spleen, 





Among the lymphocyte population, they are defined by the positive expression of CD56 and the lack 
of expression of the T cell receptor and the CD3 complex. CD56 expression is not restricted to NK 
cell population: it represents the 140 kDa isoform of the neural cell adhesion molecule (N-CAM), 
and it is also expressed by a T cell subtype and some cancer cells.
8
 Although this molecule is used 
for human NK cell phenotypic definition and selection, its role on NK cell function is still unknown. 
 
One key function in the development of NK cells is the CD56-driven migratory behavior of NK cells 
on stromal cells, forming a developmental synapse. NK cells acquire motility with progressive 
maturation, correlated with the expression of CD56 on developing NK cells.
9
 Blocking of CD56 
therefore perturbs both NK cell motility and maturation. In general CD56
+
 immune cells are also 
able to form strong immune synapses with each other through CD56 binding. For example, CD56
+
 
DCs have been shown to induce the preferential activation and expansion of CD56
+
 γδ T cells via 
CD56.
10
 In particular, homophilic interaction between CD56 molecules on CD56
+
 cells can be 
formed, including immune cells but also, for example, tumor cells. In this way, CD56
+
 CIK cells are 




 The expression of another NK cell surface molecule, the low-
affinity receptor for the Fc portion of IgG CD16 (FcγRIIIA), is also used to define NK cells; like 
CD56, its expression is not restricted to these cells. The definition of NK cells by a unique marker is 





cells, which represent sequential stages of maturation
12





 NK cells account for ~90% of the population in peripheral blood 
(PB) and are capable of potent cytotoxicity. CD56
bright
 NK cells, on the other hand, are poor 
mediators of direct cytotoxicity but are competent for cytokine production and, primarily, reside in 









Despite some common features, several NK cell subsets with specialized functions have been 
described in human and mice by using different markers.
15
 The progression of CD56
bright
 toward 
the more differentiated CD56
dim
 NK cells can be identified on the basis of the progressive down-
regulation of CD94
16
, CD62L and the expression of KIRs and CD16, while CD57 expression is 
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Figure 2. Model of human CD56dim NK-cell differentiation 
 
 
Among these markers, CD94 particular interest since useful to distinguish functionally distinct 
subsets in both human and mouse. CD94 is a type II integral membrane protein that is related to the 
C-type lectin superfamily and can covalently associate with NKG2A/C. In human, the natural ligand 











The level of CD94 expression can segregate human NK cells into three distinct subsets and defines 























Figure 3. Dissection of PB-NK cells from healthy donor by using the CD94 marker. Flow cytometry 
analysis of NK cells derived from PB of Healthy Donor, dissected on the basis of CD56 and CD94 surface 
expression levels. NK cell subsets are identified as CD94lowCD56dim (red), CD94highCD56dim (blue) and 
CD94highCD56bright (black) and numbers indicate the percentage of cells in each gate. 
 
 
NK cells function 
 
Natural killer cells are able to lyse virus-infected and transformed cells without any priming and are 
particularly activated towards targets that display low levels of major histocompatibility complex 
(MHC) class I molecules via two main cell-to-cell contact dependent mechanisms: the Antibody 
Dependent Cell Cytotoxicity (ADCC) and the Natural Cytotoxicity. 
 
The binding to a target cell is accompanied by the formation of a complex structure at the cell–cell 
interface, named immunological synapse. Following the recognition of a target cell, NK cytotoxic 
granules containing perforin (a membrane-disrupting protein) and granzymes (serine proteases) are 
secreted by a Ca2+-dependent exocytosis in the immunological synapse. This mechanism is also 
known as degranulation. Perforin polymerizes and forms a transmembrane pore that allows the 
delivery of granzymes to the cytosol where they cleave and activate different caspases leading to the 
apoptosis of the target cell.
20
 Lining the membrane of the lytic granules is the lysosomal-associated-





Has been demonstrated that the up-regulation of this molecule on NK cell membrane is a marker of 




Target cell recognition can occur through direct recognition of the target cell mediated by activating and 
inhibitory receptors or through antibody-dependent cellular cytotoxicity (ADCC) mediated via ligation of 
the CD16 receptor expressed on CD56
dim
 NK cells. ADCC is an important immune effector mechanism 
by which antigens of tumor or infected cells coated by IgG antibodies are recognized by Fcγ receptors 
present on effector cells. Thus, antibodies mediate contacts between effector and target cells allowing the 
subsequent killing of target cells. Natural Killer cells are one of the major effector cells involved in this 
mechanism due to their expression of CD16, the FcγRIIIA. In particular, CD56
dim
 NK cells, highly 
expressing this receptor, are more implicated in ADCC than CD56
bright
 NK cells. The interaction 
between CD16 and its ligand induces NK cell degranulation with the exocytosis of perforin and 
granzymes at the immune synapse. This mechanism has been well studied and is now exploited in mAb-
based cancer immunotherapy. The production of antibodies directed against specific antigens 
overexpressed by tumor cells is an active field in immunotherapy. 
 
NK cell cytotoxicity can be mediated by another mechanism that involves the direct binding between 
NK cell molecules belonging to the Tumour Necrosis Factor (TNF) family, like FasL and the soluble 
TNF-related apoptosis-inducing ligand (TRAIL), and their receptors expressed by target cells (Fas, 
and TRAIL-R). This second pathway is less implicated in the host defense against pathogens in vivo 
but is important for the elimination of auto-reactive lymphoid cells and homeostasis. Fas (CD95) is 
expressed by numerous cells and belongs to the TNF receptor family. This receptor contains a 
conserved intracytoplasmic “death domain” that, following the interaction with Fas-L, indirectly 





Natural cytotoxicity refers to the capacity of Natural Killer cells to lyse a target cell without prior 
sensitization and without antibody-mediated recognition. In 1990, Klas Karre proposed “the missing 
self” hypothesis to explain how NK cells are capable to lyse target cells lacking or displaying low 
expression of MHC class I molecules.
22
 This theory derived from the numerous experimental 
observations that tumor cells deficient for MHC class I molecules were efficiently lysed by NKs, 
conferring them a role in the control of NK cell activation. The missing self hypothesis was proposed 
before the discovery of the receptors implicated in the recognition of MHC-I molecules (KIRs, 
CD94/NKG2 and ILT). 
 
NK cell Receptors and Ligands 
 
 
Through the identification of activating and inhibitory NK cell receptors, the missing self 
theory has evolved. It is currently accepted that NK cell activation depends on an intricate balance 
































Killer-cell immunoglobulin-like receptors 
 
 
Killer cell immunoglobulin-like receptors (KIR) constitute the main group of inhibitory receptors 
expressed on human NK cells. Located on chromosome 19, stochastic expression of the KIR genes is 
epigenetically controlled via the KIR promoter.
23
 The KIR nomenclature is based on the length of 
the cytoplasmic tail, short (S) or long (L), and the number of extracellular Ig-like domains (2 or 3). 
While the long cytoplasmic tail receptors contain immunoreceptor tyrosine-based inhibitory motifs 
(ITIM), the short tails contain immunoreceptor tyrosine-based activation motifs (ITAM) that aid in 
binding to the adaptor molecule DAP12. 
 
Phosphorylation of ITIMs on inhibitory receptors results in the recruitment of tyrosine phosphatases 
which in turn dephosphorylate adaptor molecules associated with activating receptors.
24
 This 
ensures inhibitory receptor signaling dominating over activating receptor signaling. KIR bind to 
specific allelic variants of human leukocyte antigen (HLA) A, B and C, the human equivalent of 
MHC class I proteins.
25
 Non-classical HLA-F and HLA-G have also been identified as interacting 
with KIR receptors. As the highly diverse KIR locus is both polygenic and polymorphic, many 
ligands for this large repertoire of KIR receptors still remain to be discovered. 
 
For simplicity, two KIR haplotypes are used to group KIR genotypes within individuals. Haplotype 
A contains a restricted number of inhibitory receptors and one activating receptor, KIR2DS4. The 
less common haplotype B includes a larger repertoire of both inhibitory and activating receptors61. 
On top of the stochastic expression via epigenetic regulation of the KIR gene promoter, variation in 
terms of KIR gene copy number furthers adds to the diversity. The three main inhibitory receptors 











Other notable KIR-ligand interactions include KIR3DL2 binding to HLAA3/A11 and HLA-F and the 
activator receptors KIR2DS1 binding to HLA-C2 and KIR3DS1 binding to HLA-F Activating 





CD94 is a type II integral membrane protein that is related to the C-type lectin superfamily and can 
covalently associate with 5 different members of the NKG2 family (NKG2A, B, C, E, and H), but 
not with NKG2D. This association is important for the translocation of NKG2 receptors to cell 
surface and for ligand recognition. NKG2 receptors share a common structure composed of a C-type 
lectin-like domain, a transmembrane domain and a cytoplasmic segment. According to the presence 
of immunoreceptor tyrosine-based inhibitory motifs (ITIM) in their cytoplasmic domains and to their 
binding with adaptor molecules, they were classified as inhibitory or activating receptors. NKG2 and 
CD94 genes are located in a region of chromosome 12 known as “Natural Killer complex”. NKG2A 
and the alternative spliced form B contain two ITIM motifs, form a heterodimer with CD94 molecule 
and are thus inhibitory receptors. After interaction with the ligand, the tyrosine residue in each ITIM 
domain is phosphorylated leading to the recruitment and activation of SHP-1 and SHP-2 tyrosine 
phosphatases and finally blocking the NK cell activation cascade
26
 In contrast, NKG2C, E and H 
variants lack ITIM domains and are associated with the ITAM-bearing DAP12 adaptor molecule. 
Thus, CD94/NKG2C molecules form heterodimeric activating receptors. The affinity of NKG2 
receptors with ligands was investigated and seemed to be different for each receptor: in particular, 
CD94/NKG2A displayed a higher affinity for HLA-E molecules compared to CD94/NKG2C. 











Cell surface expression of HLA-E is regulated by the expression of other classical class I molecules, as 
they are the major source of HLA-E binding peptides in normal cells. In particular, signal sequence 
peptides from HLA-I molecules (HLA-A, B and C as well as the non-classical HLA-G molecule) bind to 
HLA-E allowing its surface expression. Consequently, CD94/NKG2 receptors, through the recognition of 
HLA-E, let NK cells indirectly survey the global expression of class I molecules, frequently altered in 
transformed or infected cells. The decrease of classical HLA molecules at the surface of tumor cells is a 
major mechanism involved in tumor immune escape from cytotoxic T effectors while it leads to NK cell 
activation. Conversely, non-classical HLA-E and HLA-G molecules are frequently overexpressed by 
cancer cells participating in tumor immune escape through the interaction with inhibitory receptors and 
the subsequent inhibition of NK and cytotoxic T cell (CTL) activation. The production of soluble HLA 
molecules (sHLA; classical and non-classical) have been described as another potential mechanism 
involved in cancer immune escape and in vitro studies demonstrated that sHLA could induce inhibition 
and apoptosis of NK cells. 
 
Along with NKG2C and NKG2D, a number of other activating receptors exist which play important 
roles in regulating the cytotoxic capability of NK cells. Notably these include the germline encoded 
natural cytotoxicity receptor (NCR) family consisting of NKp30, NKp44 and NKp46, CD16 and 
DNAX accessory molecule-1 (DNAM-1). 
 
Additional molecules appear to be important in the activation of NK cell cytotoxicity, among them 
NKp80, 2B4 and NTB-A. These are considered as co-receptors since their function is dependent on 













Natural Cytotoxicity Receptors (NCRs) 
 
 
Three NK cell triggering surface receptors that display a critical role in the induction of NK cell-
mediated non-MHC-restricted cytotoxicity of tumor and transformed cells have been identified. 
These important activating receptors for NK cell lytic function are named “Natural Cytotoxicity 
Receptors” (NCR). The cross-linking of NCR with specific mAb strongly increase the cytolytic 
activity in redirected killing assays, whereas blocking of NCR by mAbs inhibits NK cell cytotoxicity 
against most target cells. Furthermore, NCR surface density on NK cells correlates with the 
magnitude of cytotoxicity against NK-susceptible target cells.
28-30
 NKp30 (NCR3) and NKp46 
(NCR1) are ubiquitously expressed on resting NK cells in peripheral blood, while NKp44 (NCR2) is 
upregulated on activated NK cells in response to IL 2 stimulation. NKp46, evolutionarily conserved 
in mammals, contains two extracellular Ig domains, similar to Ig-like receptors, while NKp30 and 
NKp44 only contain one domain each. All three receptors signal via coupling to adaptor molecules, 
either FceRIg and CD3z (NKp30, NKp46) or DAP12 (NKp44). B7-H6, the ligand for NKp30, is 
expressed on tumor cell lines as well as on neutrophils and monocytes after toll-like receptor and 
pro-inflammatory cytokine stimulation. Similar to CD16, NKp30 also has immune-regulatory 
functions on top of its important role in immune surveillance. The ligands for NKp44 and NKp46 




DNAM-1, also known as CD226, is a leukocyte adhesion molecule involved in the induction phase 
of NK cell activation. DNAM-1 gene is encoded on chromosome 18 and is expressed by NK cells, T 








Its structure is characterized by an extracellular portion with two Ig-like domains and a cytoplasmic 
tail containing three tyrosine residues. Following DNAM-1 cross-linking, tyrosines are 
phosphorylated and NK cell cytotoxicity is triggered. Interestingly, DNAM-1 expression is 
dependent on the surface expression of lymphocyte function associated-antigen 1 (LFA-1).
31
 In 
humans, DNAM-1 expression is coordinated with LFA-1 undergoing conformational changes, as 
they co-localize at the immune synapse. 
 
Two ligands of DNAM-1 have been identified: the poliovirus receptor (PVR; CD155) and Nectine-2 
(CD112). These molecules are strongly expressed by tumor cell lines of epithelial and neuronal 
origin like carcinomas, melanomas and neuroblastomas.
32
 In association with NCR or NKG2D 







 Its role in anti-tumor immunity is prominent when 







































The anti-MM potential of NK cells has been of rising interest in recent years. Although it has been 
reported that NK cell recognition and killing of MM cells mainly involves the activating receptors 
DNAM-1, NKG2D and/or NKp46, MM cells utilize specific immunoevasive strategies to reduce NK 
cell recognition and cytotoxicity. The presence of high levels of both classical HLA class I and 
HLA-E on MM cells can efficiently provide inhibitory signaling, mediated by KIRs and 
CD94/NKG2A, respectively (Figure 5), therefore representing an important stumbling block for NK 


























The aim of this study was to better define the distribution and the specific properties of NK cell 
subsets during MM disease. Here we analyzed NK cells features in the bone marrow and peripheral 
blood of newly diagnosed, untreated, MM patients and during MM progression. Moreover, we 
analyzed different NK cell subsets on the basis of their receptor expression, including CD94/NKG2A 
molecules, representing one of the dominant NK cell inhibitory signal involved in MM resistance to 
NK cell killing. 
 
14 





Peripheral blood (PB) and bone marrow (BM) samples were obtained from a cohort of 23 newly 
diagnosed, untreated, MM pts (Table 1). Additional PB and BM samples were also collected from pts 
with MGUS (8 PB and 4 BM samples) and sMM (5 PB and 3 BM samples). All the pts were 
admitted at the Hematology Unit of University Hospital Policlinico G. Martino, Messina. The study 
was approved by the institutional ethics committees and all participants gave written informed 
consent according to the Declaration of Helsinki. 
 
PTs Age (years) Clinical Monoclonal % PCs in BM CD56 
no. /Gender Stage Ig  expression 
  (ISS)   on MM cells 
      
1 60/M III IgG κ 50 ++ 
      
2 65/M I IgG κ 28 ++ 
      
3 59/M III IgG κ 60 ++ 
      
4 60/F I IgG κ 60 + 
      
5 65/F III IgA κ 50 + 
      
6 67/F III IgG κ 40 ++ 
      
7 62/F II IgG κ 70 + 
      
8 60/M III IgG κ 70 ++ 
      
9 54/F I IgG κ 35 ++ 
      
10 65/M I IgG κ 50 ++ 
      
11 60/F II IgG κ 30 ++ 
      
12 62/M II IgA κ 35 ++ 
      
13 58/F I IgG λ 60 + 
      
14 65/M II IgG κ 50 ++ 
      
15 70/M I IgG κ 40 ++ 
16 62/F III IgA κ 50 ++ 
      
17 65/F III IgG λ 40 ++ 
      
18 63/F II IgA κ 45 ++ 
      
19 64/M III IgG λ 38 ++ 
      
20 60/F III IgG λ 80 + 
      
21 61/F III IgG λ 38 ++ 
      
22 65/M III IgG κ 30 + 
      
23 63/F II IgG λ 35 + 
      
 
 
Table 1. Patient’s baseline characteristics and CD56 expression on BM-MM cells.  




Cell Purification and Isolation 
 
Peripheral blood mononuclear cells (PBMCs), as well as bone marrow mononuclear cells (BMMCs), 
were isolated by Ficoll Hypaque density gradient centrifugation from heparinized PB and BM 
samples (30 min, 25 °C, 400 × g). To isolate MM cells (which reside in BM and hardly circulate in 
PB) BMMCs from MM pts were stained with anti-CD38 PerCp-Cy5.5 (clone HIT2) and anti-CD138 





To isolate NK cells, PBMCs from MM pts and/or HDs were stained with anti-CD56 APC-Vio770 





 cells. In selected experiments, NKp46 has been employed as additional marker to 
identify, count and/or sort NK cells. The gating strategy to identify and/or sort both NK cells and 
plasma cells in the BM is shown in Figure 6. Alternatively, human NK cells were previously isolated 
by negative magnetic separation (NK Cell Isolation Kit/ Miltenyi). Cell populations sorted either by 
























Figure 6. Gating strategy used to identify and/or sort both NK cells and MM cells in BM. Representative 
flow cytometry dot plots of gating strategy used to identify and /or sort NK cells and MM cells in BM. MM 
cells were isolated by gating on CD38highCD138+cells. NK cells were isolated as CD56+CD3− cells after 





Multicolor Flow Cytometry 
 
To investigate the phenotype of NK cells in MM pts, PBMCs or BMMCs were stained with the 
following mAbs: anti-CD94 FITC (clone HP3D9), anti-CD57 PE (clone NKI), anti-CD16 PeCy5.5 
(clone 3G8), anti-CD19 APC-R700 (clone HIB19), anti-CD62L PE (clone SK11), anti-CD69 
PeCF594 (clone FN50), anti-HLA-DR APC-H7 (clone L243), anti-NKp46 APC (clone 9E2), anti-
NKp44 Alexa Fluor 647 (clone p44-8), anti-CD38 PerCp Cy5.5 (clone HIT2) and anti-CD138 PE 
(clone M115), purchased from BD Biosciences; anti-CD56 APC-Vio770 (clone REA196), anti-CD3 
Vioblue (clone BW264/56), anti-CD45 Viogreen (clone 5B1), anti-NKp30 PE (clone AF29-4D12), 
anti-NKG2D PE-Vio770 (clone BAT221), anti-NKG2A APC (clone REA110), anti-CD158a/h PE 
(KIR2DL1/DS1) (clone 11PB6), anti-CD158b PE (KIR2DL2/DL3/DS1) (clone DX27) from 
Miltenyi; anti-CD56 PC7 (clone N901, NKH-1) and anti-CD3 ECD (clone UCHT1) from Beckman 
Coulter. For surface markers, cells were stained for 30 min at 4°C. For indirect labeling, the 
following mAbs were used: anti-HLA class I (clone A6-136, and clone W632), anti-CD56 (clone 
A6-220), anti-DNAM-1 (clone F5), anti-NKp46 (clone KL247), anti-NKp30 (clone F252), anti-
NKG2D (clone BAT221), anti-LIR/LT2 (clone F278). All the antibodies used for indirect labeling 
were produced in our laboratory or kindly provided by Prof. Alessandro Moretta (University of 
Genoa, Italy). For indirect labeling, cells were first incubated with the primary antibody for 30’ at 4 
°C. After incubation, cells were extensively washed and incubated with isotype-specific 
fluorochrome-conjugated secondary antibody for 30’ in the dark. NK cell proliferation was assessed 
by the expression of the intranuclear marker Ki67, performing fixation/permeabilization procedures 
according to manufacturer’s protocol (eBioscience) followed by staining with an anti-Ki67-BV421 
mAb (clone B56) purchased from BD Biosciences. Dead cells were excluded by staining with 




Sample acquisition was performed on FACSCantoII (BD Biosciences) or Gallios (Beckman Coulter) 





The human MM cell lines U266B1 and MM1S were kindly provided by Prof. F. Cimino (University 
of Messina), whereas K562 (chronic myelogenous leukemia, CML) and 721.221 (B-lymphoblastoid 
cell line, LCL) were provided by Prof. M.C. Mingari. All the above cell lines were maintained in 
RPMI 1640 with 10% fetal bovine serum (FBS) and supplemented with penicillin (100 U/ml), 
streptomycin (100 μg/ml). 
 
In order to assess the relevance of NCAM-1 in the interaction between NK cells and tumor cells, 
K562 cell line was transfected with the expression construct pCDNA3.1/V5/His-TOPO-NCAM-1 
containing the cDNA coding for NCAM-1 (NM_181351), utilizing Lipofectamine 2000 
(ThermoFisher) following manufacturer’s instructions. After 72 h, NCAM-1 expression was 
analyzed by flow cytometry using anti-CD56 PC7 mAb. Transfected cells were cultured in the 
presence of 1.2 mg/ml G418 (Calbiochem) in order to obtain stable transfectants. At the end of the 








 NK cell subset, NK cells isolated from 
healthy donors (HDs) were plated at 1x10
5
/well in 96-well V-bottom plates, with or without primary 
 
MM cells (i.e. freshly isolated from pts BM) or MM cell lines (U266B1, MM1S), 721.221 
lymphoblastoid cell line, K562 erythroleukemia cell line, at NK cell to target cell (E:T) ratio of 1 to 





In selected experiments, co-cultures were preceded by incubation of cells (either effector or target 
cells) with blocking mAbs against NKp46 (IgM, clone KL247), NKp30 (IgM, clone F252), NKG2D 
(IgG1, clone BAT221), DNAM-1 (IgM, clone F5), CD56 (IgM, clone A6-220) (kindly provided by 
Prof. A. Moretta), or isotype matched controls. 
 
To assess NK-cell cytolytic potential and IFN-γ production, CD107a degranulation assay and 
intracellular IFN-γ staining were performed by co-incubating NK cells isolated from both HDs and 
 
MM pts, with primary MM cells or U266B1 cell line or K562. In selected experiments, co-cultures were 
preceded by incubation of target cells with HLA class I (IgM, clone A6-136) blocking mAb. Co-cultures 
were performed, at an E:T ratio of 1:1, in the presence of anti-CD107a APC (BD Biosciences). After 1 h, 
Golgi Stop (1:1500 dilution, BD Biosciences) was added, and cultures were incubated for an additional 5 
hrs. Upon surface staining, cells were fixed and permeabilized (Cytofix/Cytoperm Kit, BD Biosciences) 
according to the manufacturer’s protocol and incubated with anti-IFN-γ PE-conjugated mAb (BD 
Biosciences) for 30 min at 4°C. Surface CD107a and intracellular IFN-γ expression were finally 
assessed by flow cytometry on effector cells. To detect spontaneous degranulation and constitutive 
expression of cytokine, NK cells incubated without target cells were analyzed as control. 
 
To assess the killing capacity of HDs- and MM-NK cells we performed a flow cytometric and non-
radioactive target-based assay. In this assay, NK cells isolated from both HDs and MM pts were co-
incubated at an E:T ratio of 1:1 with a target tumor cell lines (K562 or U266B1). The target cells 
were pre-labeled with a red fluorescent dye PKH-26 (Sigma-Aldrich), according to the 
manufacturer’s instructions, to allow their discrimination from the effector cells (NK cells). After 
short term in vitro incubation (3h), killed target cells are identified by a 7AAD stain, which 
specifically permeates dead cells. Data analysis is performed first by gating on PKH-26 positive 




The following control conditions were included in this assay: Target cells only and Tween mediated 
killing of target cells. The target cells death was calculated on the bases of the ratio: [(% sample 





A paired Student’s t-test was used to evaluate statistical significance. P-values <0.05 were 























































NK cells are increased in both PB and BM of MM patients 
 
In order to analyse NK cells in MM disease, newly diagnosed, not treated pts, were enrolled in the 
study. We first determined the frequency of NK cells in both PB and BM compartments and 
compared it with the one in healthy donors (HDs). We found a higher amount of NK cells in both PB 
(18.2%±1.153% vs 10.37%±0.57%, P=0.002) and BM of MM pts (17.57%±0.44% vs 
9.54%±0.44%, P=0.002) (Figure 7A), whereas total leukocyte and lymphocyte counts did not show 
significant differences between MM pts and HDs. Remarkably, a consistent fraction of NK cells in 
both PB and BM of MM pts expressed Ki67 (Figure7B), therefore indicating that NK cells in these 
















Figure 7. Assessment of NK cell frequency and proliferation in MM patients. (A) PBMCs and BMMCs of  
MM pts or HDs were analysed for the frequency of NK cells (gated on total live CD56+ CD3- lymphocytes). Box 
and whiskers plots represent percentage of NK cells in PB (MM=n.23; HD=n.23) and BM (MM=n.23; HD=n.3) 
samples; (***: p< 0.001), Student’s t-test. (B) Proliferating NK cells were assessed by Ki67 staining in PBMCs and 
BMMCs derived from MM pts and PBMCs from HDs as control. Representative dot plots show the percentage of 
Ki67+ cells among total NK cells. Data derived from 23 MM pts are summarized in the right panel and compared 







 NK cell subset is enriched and proliferating in MM patients 
 
 
We then analyzed the distribution of major NK cell receptors and other relevant molecules expressed by 
NK cells of MM pts. As a whole, MM-NK cells displayed features consistent with a more activated and 
differentiated phenotype, highlighted by the up-regulation of both activating receptors and 
21 
activation markers and including a lower amount of CD62L
+
 cells and a higher frequency of 
CD57
+
 cells (Figure 8).
17,19,39
 In agreement with these observations, NK cells expressing 
significant levels of CD94 molecules were drastically decreased in MM pts and this distribution was 
accompanied by a concomitant lower frequency of NKG2A
+
 NK cells, while NK cells expressing 


















































Figure 8. Phenotypic characterization of PB NK cells from MM patients. Flow cytometric analysis of the 
indicated markers assessed on NK cells freshly isolated from PB of MM pts or HDs. Data from analyses of 
at least 20 pts are summarized in graphs beside each flow cytometry histogram overlay; bars represent the 
mean values of the percentage of positive cells or mean fluorescence intensity (MFI) ± SEM for the indicated 
cell marker (*: p<0.05; **: p< 0.01; ***: p< 0.001). Student’s t-test.  
22 
Considering that CD94 density identifies three functional distinct NK cell subsets and the relevance 
of CD94/NKG2A inhibitory molecules in the recognition of MM cells, we further dissected NK cell 




 subset was consistently increased in 
both PB (63.3%±7.8% vs 35.2%±9.8%, P=0.001) and BM (65.9%±7.4% vs 36.2%±9.4%, P=0.001) 
of MM pts, when compared to NK cells of HDs (Figure 9). Accordingly, also the amount of 



























Figure 9. (A) Representative dot plots of NK cells from PB and BM of MM pts and HDs showing the 
percentage of CD94lowCD56 dim NK cells. Box and whiskers plots represent the frequency of 
CD94lowCD56dim NK cells in PB or BM of 23 MM pts compared to HDs (PB=n.20, BM=n.3), (***: p< 
0.001), Student’s t-test. In the right panel, representative dot plots of NK cells from PB and BM of MM pts 




Further phenotypic analysis conducted on NK cell subsets dissected according to CD94 expression 
confirms the higher activation status of CD94lowCD56dim subset compared to the other two CD94high 
counterparts. Among the different markers, it is noteworthy that, in MM pts, DNAM-1 AND 










Figure 10. Phenotypic characterization of PB-NK cell subsets from MM patients dissected on the basis 
of CD94 expression. NK cells were identified as CD94lowCD56dim (upper panel), CD94highCD56dim 
(middle panel) and CD94highCD56bright (low panel) and flow cytometric analysis of the indicated markers 
was performed on freshly isolated PB NK cells of MM pts or HDs. Histograms shown are representative of 
data obtained from the analyses of at least 20 pts/HDs. 
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 NK cells was accompanied by their 




 NK cells  
based on the expression of the main KIRs (namely KIR2DL1/DS1 and KIR2DL2/DL3/DS2)                                                                                                                                                                                          






 NK cells (Figure 11, lower 






 NK cells, devoid of the main 

























Figure 11. Analysis of proliferative rate of NK cells isolated from PB and BM of MM pts and from PB of 
HDs based on the expression of main inhibitory receptors (upper row). Numbers adjacent to gates indicate 
the frequency of CD94lowCD56dim Ki67+ NK cells. Lower row shows Ki67 + cells within the 

























 proliferating NK cells is an early hallmark of MM disease 
 
Because MM disease is often preceded by precursor conditions, namely MGUS and sMM, we 
analyzed MM-NK cell features during MM progression. Interestingly, the modifications detected in 
 
MM pts were already present in MGUS pts and apparently accumulated along disease progression 
(Figure 12A). Total NK cell frequency, CD94
low
 NK cells, and Ki67
+
 NK cells were increased in 
MGUS and sMM pts, both in PB and BM, reaching however their highest levels in MM pts (Figure 
5A). Figure 12B shows the modifications of NK cell compartments progressively occurring along 








































Figure 12. NK cell features during the early phases of disease: from MGUS to MM. (A) Comparative 
analysis of frequency of total NK cells (upper row), frequency of CD94lowCD56dim NK cells (middle row) 
and frequency of Ki67+ NK cells (lower row) in PB and BM of MGUS, sMM and MM pts compared to 
HDs. (B) Representative patient evolving from MGUS to sMM and eventually to MM. Dot plots depict 
frequency of CD94lowCD56dim NK cells and Ki67 analyzed on NK cells from both PB and BM of the 








 NK cells represent the main cytotoxic subset against autologous MM cells 
 
We then investigated the functional capability of MM-NK cells against MM cells. To this aim, we 
used either primary MM cells or U266B1 cell line as cellular target for both HD- and MM-NK 
cells. MM-NK cells were more competent than HD-NK cells in both cytolytic ability and IFN-γ 
secreting properties against both allogeneic primary MM cells, U266B1 (Figure 13A-B), 
































Figure 13. Degranulation ability and IFN-γ production of NK cells from MM patients. (A) NK cells 
isolated from PB of MM pts or HDs were co-cultured with allogeneic primary MM cells or U266B1 cell line 
at an E/T ratio 1:1 for 6hrs. In the upper panel, degranulation activity was assessed by evaluating the 
percentage of CD107a+ NK cells. One representative experiment out of eight is shown. Summary of data is 
represented in the bars as mean ± SEM of CD107a+ cells. (*: p<0.05), Student’s t-test. In the lower panel, 
IFN-γ production by NK cells was analysed by flow cytometry. One representative experiment out of eight is 
shown. Results of all experiments performed are summarized in the bars as mean ± SEM of IFN-γ+ cells. (*: 
P<0.05), Student’s t-test. (B) NK cells isolated from PB of MM pts or HDs were co-cultured with K562 at an 
E/T ratio 1:1 for 3hrs. Killing capability of NK cells was assessed by evaluating target cell death upon co-
culture. Gating strategy for detection of target cells. The initial gate was set in PKH26/SSC-A plot. U266B1 
are gated as PKH26+ events. Dead target cells (7AAD) are gated in the subsequent 7AAD/SSC-A plot within 







Nevertheless, the cytolytic activity of MM-NK cells against autologous MM cells was significantly 
defective (Figure 14). This flawed cytotoxic capability against autologous MM cells seems to be 
dependent on the high level of HLA-class I molecules expressed by MM cells, which resulted, as a 


















Figure 14. Degranulation ability of pts-derived NK cells against matched autologous or allogeneic MM 
cells. In the left panel data from 10 independent experiments are represented as mean ± SEM of CD107a+ 
positive cells (*: P<0.05), Student’s t-test. MM cells used for the degranulation assay were further analyzed 
for the expression of total HLA class I (clone W632, IgG) by flow cytometry. One representative patient is 
shown where MM cells were compared with healthy B plasma cells isolated from human tonsil (right panel). 
 
 
Masking of total HLA-class I molecules on MM targets resulted in a relevant recovery of NK cell 
degranulation (Figure 15). 
 





 NK cells mostly account for the residual degranulating activity against MM 
cells, while CD94
high
 counterpart showed cytolytic ability only upon blocking of total HLA-I 






































Figure 15. (Upper panel): degranulation ability of pts-derived NK cells was analyzed against autologous MM 
cells, either in the absence (isotype control, IgM) or in the presence of an anti-HLA-I blocking antibody (clone 
A6-136, IgM). One representative experiment is shown and numbers in each gate represent the percentage of 
CD107a+ cells. Data from six independent experiments are summarized in the bars and presented as mean ± SEM 
of CD107a+ NK cells (*: P<0.05), Student’s t-test. In the lower panel, CD107a expression on pts-derived NK 
cells upon co-culture with autologous MM cells, in the absence or presence of an anti-HLA class I blocking 















 NK cell subset, we evaluated whether MM cells could directly be responsible 
for the observed effect. 
 
After 24h co-culture of HD-NK cells with primary MM cells (i.e. freshly isolated from pts BM) or 





 NK cells was increased and this effect was specifically induced by MM cells, 
since we did not detect any significant increase when NK cells were co-cultured with other highly 















 NK cell subset in the absence of any exogenous growth factors, while 
this proliferation response was not detected employing K562 cell line in the co-culture (Figure 16B). 




 HDs-NK cell subsets before co-culturing with 
 




 NK cell subset proliferated than CD94
high
 NK cell subsets (Figure 16C). These 




 NK cells was dependent on 





















Figure 16. Mechanisms determining the expansion of CD94lowCD56dim NK cell subset induced by MM 
plasma cells (A) Frequency of CD94lowCD56dim NK cells among total NK cells from HDs upon 24h co-culture 
with or without allogeneic MM cells isolated from the BM of four distinct pts (upper panel) or with the indicated 
tumor cell lines (lower panel). E/T ratio of 1:1. (B) In vitro proliferation of NK cells from HDs cultured in the 
absence or presence of primary MM cells, U266B1 and K562 cell lines. The Ki67 expression on NK cells is 
shown in relation to CD94 molecule distribution. Summary of data from three independent experiments is shown 
as mean ±SEM (***: p< 0.001). Student’s t-test. (C) . CD94high and CD94low HDs-NK cells were sorted and co-
cultured for 24h with MM cells. One representative experiment out of three is shown. 
 
 
To gain more insight into the specific mechanism underlying the accumulation of CD94
low
 subset 
induced by MM cells, we determined CD94 expression upon 24h culture of NK cells in the 





 subset, suggesting that cell-to-cell contacts between NK cells and MM cells 
were required. 
30 
Thus, we assessed the contribution of the main NK cell activating receptors that might potentially 
be involved in the interaction with MM cells
33
. Remarkably, blocking DNAM-1 receptor 




 NK cells, while inhibition of NKp46, 




 NK cell subset 
accumulation (Figure 17A). Since the ligands of DNAM-1 are widely expressed in several other 




 NK cell expansion, we wondered whether 
MM cells may additionally provide some specific signal that might account for this peculiar 
accumulation in MM pts. NCAM-1, also known as CD56, is a glycoprotein typically expressed on 
NK cells but also present on neoplastic plasma cells.  
 
CD56 has been implicated as having a role in cell-cell adhesion by homophilic interaction. Recently 
it has been reported that the expression of CD56 in breast cancer enhance the formation of cytotoxic 
immunological synapse becoming a factor responsible for the sensitivity to NK cell killing. In light 
of this, we hypothesized that CD56, known to be commonly expressed also by MM cells, might 
account for the observed effect on NK cell activation. 
 





cells from patient’s BM (Figure 17B) and we observed that only CD56
+
 MM cells were able to 
induce CD94
low
 accumulation (Figure 17B). Accordingly, the addition of CD56/NCAM-1 





cells and, remarkably, their proliferation in response to MM cells (Figure 17C-D). 
 
To further support the relevance of CD56 in the observed proliferation of NK cells, we stably 
transfected the cDNA coding for CD56 protein in the highly susceptible NK cell target K562 cell 
line. Reliable expression of CD56 was confirmed by staining with anti-CD56 mAb (Figure 17E). 
Consistent with our hypothesis, K562 cells expressing CD56 acquired the ability to induce 
proliferation of NK cells, while parental K562 were unable to mediate the same effect (Figure 
17E), confirming that CD56-CD56 interaction between tumor and NK cells can play a relevant role 





















Figure 17. Mechanisms determining the expansion of CD94lowCD56dim NK cell subset induced by MM 
plasma cells. (A) NK cells from HDs were cultured with U266B1 cells for 24h in the presence of blocking mAbs 
for the indicated receptors (anti-NKp46, anti NKp30, anti-NKG2D, anti-DNAM-1) or isotype controls (IgM ctrl). 
Histograms represent delta (Δ) values ± SEM of CD94lowCD56dim NK cells calculated as the percentage of 
CD94lowCD56dim NK cells cultured with U266B1 subtracted the percentage of CD94lowCD56dim NK cells 
cultured without a target, in each condition. (B) CD56neg and CD56+ MM were sorted from patient’s BM (as 
shown in the left dot plot) and co-cultured for 24h with HD NK cells (right dot plots). One representative 
experiment out of three is shown. (C) NK cells from HDs were cultured with MM cells isolated from pts’s BM for 
24h in the presence or absence of blocking mAb for CD56/NCAM-1 and then analyzed for the expression of 
CD94 by flow cytometry. Histograms show representative expression of CD94 in cultured NK cells in the 
presence of blocking mAb for CD56/NCAM-1 (A6-220) or IgM control. Bars represent delta  
(Δ) values ± SEM of CD94lowCD56dim NK cells calculated as the percentage of CD94lowCD56dim NK cells 
cultured with MM cells subtracted the percentage of CD94lowCD56dim NK cells cultured without a target. 
(D) In vitro proliferation of HDs NK cells cultured with MM cells in the absence or in the presence of an 
anti-CD56/NCAM-1 blocking antibody. Numbers adjacent to gates indicate the frequency of Ki67+ NK 
cells. Bars represent data from four experiments shown as mean ± SEM of Ki67+ cells. Student’s t-test. (**: 
p< 0.01). E) In vitro proliferation of HDs NK cells co-cultured (24h) with either K562 or K562-CD56+ cells. 
A representative experiment and mean of data ± SEM from three independent experiments are shown (**: p< 






























Immune effector cells, including NK cells, are known to play a crucial role in the control of tumor 
growth. The therapeutic potential of NK cells against cancers has stimulated their study and led to 
the discovery of several NK cell subsets, each of which is endowed with different functions. 
 
The precise identification of tumor-associated NK cell subsets that are specifically activated along 
the disease may provide information regarding an ongoing immune response against the tumor and 
might be of help to identify an immuno-editing process occurring in a given patient.
40 
 
Although several studies have shown that tumor-associated NK cells in advanced disease can have 
profound functional defects and therefore be inefficacious against tumor, the further level of 
complexity due to the wide heterogeneity and plasticity of NK cells can allow us to identify specific 
NK cell subsets endowed with enduring antitumor activity.
41 
 
Thus, the challenge is to understand which subpopulations mediate the antitumor response and which 
environmental factors can modulate their activity. In this regard, a large body of evidence reveals 
enrichment of selective NK cell subsets in both solid and hematological tumors
42
, indicating that the 
outcome of NK cell antitumor effector functions is not always predictable, since largely dependent on 
the specific tumor microenvironment. Although the mechanisms underlying the enrichment in specific 
NK cell subsets have not always been fully elucidated, it is conceivable that neoplastic cells or tumor-
derived factors could take part in this process. In MM disease, tumor plasma cells appear to be mainly 
confined to the microenvironment of the BM and are rarely detected in the periphery. 
 
Since several studies indicated that tumor-induced impairment of NK cell functions 
correlates with alterations of NK cell subset distribution, we analyzed different NK cell subsets on 
the basis of their receptor expression, including CD94/NKG2A molecules, one of the dominant NK 








 subset in both PB and BM of 




 NK cell subset showed the 
highest cytotoxic potential against autologous MM cells and, interestingly, these cells were 
proliferating in MM pts, thus suggesting they can undergo in vivo activation in pts. 
 
Our data show that MM-associated NK cells are fully competent per se, at least in the disease 
stages included in this study, ranging from I to III, but most of them lose their cytotoxic potential in the 
autologous setting, most likely because of the high expression of HLA class I molecules displayed by 





 NK cells maintain the capability to degranulate against autologous MM. Although in 
vitro studies have demonstrated a higher killing potential of KIR/ligand mismatched NKG2A
neg
 NK 
cells against MM cells
38
, an accurate prediction of NK cell activity in pts was lacking. Our data not only 
corroborated previous reports but also provided in vivo evidence for a strong anti-myeloma activity of a 
specific NK cell subpopulation devoid of the main inhibitory receptors. 
 




 NK cell subset accumulation also in MGUS and 
smoldering MM suggests an active role of NK cells not only in MM but also in the early phase of 
disease development. These findings represent an interesting observation that calls for further 
investigation considering that these initial phases of the disease are not currently treated and a 
future NK cell-based strategy might be envisaged for these precursor forms with the aim of 
blocking or, at least, slowing down the progression of the disease. 
 
Altogether, these findings clearly highlight the relevance of inhibitory receptors, including 
NKG2A/CD94, in the anti-MM immune response. NKG2A has recently been identified as an 
immune checkpoint therapeutic target for both T cells and NK cells leading to the ongoing clinical 







In this context, it has been recently shown that the use of novel anti-NKG2A mAbs in combination 
with anti-PD-L1 mAbs had a synergistic anti-tumor effect, improving the control of tumor 
growth.
43,44
 Another approach to bypass NKG2A-mediated inhibition is the generation of highly 
functional NK cells lacking NKG2A, achieved by using modern gene-editing methodologies based 
on meganucleases, TALEN, or CRISPR/Cas9. The NKG2A
null
 cells generated in this way had a 
superior antitumor capacity compared to that of their NKG2A
+
 counterparts and could induce, in 
mice, a durable tumor remission.
45 
 
More in general, novel NK cell-based immunotherapeutic strategies are now oriented to the 
identification, isolation, expansion, and administration of multifunctional NK cell subsets with high 
anti-tumor potential. In the case of MM, expansion, and infusion of a high number of 
CD94/NKG2A
neg
 NK cells could represent a way to optimize NK cell therapy and thus improve its 
efficacy. 
CD56 expression is not restricted to NK cell population since it is also expressed by a T cell 
subtype and some cancer cells. Our current data highlighted the relevance of CD56 molecule as an 
activating signal provided by tumor plasma cells to NK cells. 
Being an adhesion molecule, CD56 is involved in cell-to-cell interactions through multiple 
cis and trans homophilic binding.
46,47
 CD56+ immune cells are able to form strong immune 
synapses with each other through CD56 binding. For example, CD56+ DCs have been shown to 
induce the preferential activation and expansion of CD56+ γδ T cells via CD56. Otherwise, 
homophilic interaction between CD56 molecules can also occurs between immune cells and cancer 
cells. For instance, CD56 expressed by cytokine-induced killer cells (CIK) confers them a stronger 
cytotoxic effect against CD56+ leukemia cells.
 11
 Moreover, exploiting fluorescence microscopy, a 
recent study clearly showed that CD56 expression in breast cancer is associated with 
immunological synapse and granzyme B transfer to target cells, thus concluding that CD56 
enhances the formation of cytotoxic immunological synapse.  
 
35




 NK cells displayed a high proliferative rate in these pts is of 
particular interest since this NK cell subset has been previously associated with a more differentiated 
phenotype endowed with low proliferative potential, at least upon cytokine stimulation.
17
  




 NK cells are able to actively proliferate in vitro upon 
interaction with MM cells and CD56 signal is critical for inducing this effect.  
Our data also demonstrate that DNAM-1 activating receptor is required to induce the accumulation and 
a proper activation of CD94lowCD56dim NK cells by MM cells. The immunological synapses forming 
between NK cells and target cells are extremely relevant to obtain a proper NK cell activation. In this 
context, the homophilic interaction between CD56 molecules in trans seems conferring to MM cells a 
particular activating potential for NK cells. Therefore, CD56 homophilic binding between NK and MM 
cells occurs and represents an additional activating signal able to improve myeloma cell recognition by 
NK cells and, at the same time, a critical factor to prompt their proliferation upon interaction with target 
cells. 
In conclusion, our current results represent an advance in understanding the crucial signals involved in 
anti-MM response by NK cells, providing further support for the clinical employment of anti-NKG2A 
mAbs in the treatment of these pts and, potentially, also of those in the earlier stages of the disease. This 
information might as well be useful for designing novel and more effective NK cell-
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